Under the supervision of established investigator Dr. Julian Lum, this project will explore novel metabolic regulators of T cells, a type of immune cells involved in the anti-tumour immune response.

Immune therapy is seen as a promising option for ovarian cancer treatment, due to the positive correlation between tumour immunogenicity and survival in ovarian cancer patients. However, although many immune-based treatments have been tested for ovarian cancer (e.g. checkpoint blockade and CAR-T cell therapy), none have improved patient survival rates to date. This project aims to address the urgent, unmet need to design novel strategies for immune therapy for ovarian cancer treatment.